Lu AF95245

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

MigraineThyroid Eye DiseaseMultiple System AtrophyCongenital Adrenal Hyperplasia

102 competitors in Migraine

#DrugCompanyPhaseTrials

1

Zonegran

AAzurity Pharmaceuticals

Phase 3

32

Effient

CCosette Pharmaceuticals, Inc.

Phase 3

13

Triptans

Pfizer

Phase 3

24

Aspirin /d

TThe First Affiliated Hospital with Nanjing Medical University

Phase 3

15

Lu AF95245

Lundbeck

Phase 2

36

Flunarizine

AAspartes Pharmaceuticals, Inc.

Phase 3

97

BAT7104

Teva

Phase 3

18

Tizanidine Hydrochloride

EElan Pharmaceuticals

Phase 3

19

Bayer Aspirin

Bayer

Preclinical

210

Cervidil

Pfizer

Preclinical

1Show 29 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Schizophrenia8 trials

Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia

Completed·Lundbeck·Phase 1·NCT02202226·96 enrolled

Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

Completed·Lundbeck·Phase 1·NCT02202213·47 enrolled

Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

Terminated·Lundbeck·Phase 2·NCT03793712·168 enrolled

Show 5 more trials

Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia

Completed·Lundbeck·Phase 3·NCT02892422·528 enrolled

Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

Completed·Lundbeck·Phase 2·NCT00810667·124 enrolled

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

Completed·Lundbeck·Phase 3·NCT02717195·1,098 enrolled

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

Terminated·Lundbeck·Phase 3·NCT03230864·119 enrolled

Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms

Terminated·Lundbeck·Phase 2·NCT03929497·96 enrolled

ART4 trials

Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants

Terminated·Lundbeck·Phase 1·NCT05177029·24 enrolled

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

Completed·Lundbeck·Phase 1·NCT05304910·52 enrolled

A Study Investigating Lu AG06474 in Healthy Young Participants

Terminated·Lundbeck·Phase 1·NCT05943327·56 enrolled

Show 1 more trial

A Study to Evaluate a New Tablet Formulation of Lu AG06466 in Healthy Participants

Completed·Lundbeck·Phase 1·NCT05028673·16 enrolled

Adult4 trials

A Study Investigating Lu AG22515 in Healthy Adults

Completed·Lundbeck·Phase 1·NCT05136053·58 enrolled

A Trial Investigating Lu AF82422 in Healthy Chinese and Caucasian Adults

Completed·Lundbeck·Phase 1·NCT06258720·24 enrolled

A Trial Investigating Lu AF28996 in Healthy Adult Participants

Completed·Lundbeck·Phase 1·NCT06277609·22 enrolled

Show 1 more trial

A Trial Investigating the Pain-relieving Properties of Lu AG06474 in Healthy Adult Participants

Completed·Lundbeck·Phase 1·NCT06077786·26 enrolled

Women4 trials

Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

Completed·Lundbeck·Phase 1·NCT04405323·16 enrolled

Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State

Completed·Lundbeck·Phase 1·NCT03670082·10 enrolled

Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women

Completed·Lundbeck·Phase 1·NCT01676571·16 enrolled

Show 1 more trial

Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women

Completed·Lundbeck·Phase 1·NCT03103646·22 enrolled

Alzheimer's Disease3 trials

Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease

Terminated·Lundbeck·Phase 1·NCT02388152·50 enrolled

Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease

Completed·Lundbeck·Phase 2·NCT01019421·278 enrolled

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

Completed·Lundbeck·Phase 1·NCT04149860·86 enrolled

32 more indications

Major Depressive Disorder3 trials

Dose-finding Study With Lu AA24530 in Major Depressive Disorder

Completed·Lundbeck·Phase 2·NCT00599911·652 enrolled

Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder

Terminated·Lundbeck·Phase 2·NCT00766870·35 enrolled

Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder

Completed·Takeda·Phase 3·NCT01395147·119 enrolled

AIN3 trials

Binding and Effects of Lu AG06466 in the Brain of Healthy Men

Completed·Lundbeck·Phase 1·NCT05219838·8 enrolled

Binding of Lu AG06466 in the Brain in Healthy Men

Completed·Lundbeck·Phase 1·NCT04419636·16 enrolled

A Study in Healthy Men to Investigate Uptake and Distribution of Lu AF88434 in the Brain

Completed·Lundbeck·Phase 1·NCT04538014·8 enrolled

Migraine3 trials

A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

Completed·Lundbeck·Phase 1·NCT06578585·43 enrolled

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Active, not recruiting·Lundbeck·Phase 2·NCT06323928·874 enrolled

A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Completed·Lundbeck·Phase 2·NCT05133323·237 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression

Terminated·Lundbeck·Phase 2·NCT00622245·166 enrolled

Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

Terminated·Lundbeck·Phase 2·NCT00771134·105 enrolled

Ischemic stroke2 trials

Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

Completed·Lundbeck·Phase 1·NCT00756249·16 enrolled

Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

Completed·Lundbeck·Phase 1·NCT00870844·24 enrolled

Interaction2 trials

Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men

Completed·Lundbeck·Phase 1·NCT04713254·15 enrolled

Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.

Completed·Lundbeck·Phase 1·NCT02199431·20 enrolled

Parkinson's Disease (PD)2 trials

Lu AF28996 in Participants With Parkinson's Disease (PD)

Completed·Lundbeck·Phase 1·NCT04291859·57 enrolled

A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD)

Completed·Lundbeck·Phase 1·NCT06004180·6 enrolled

Cognitive impairment1 trial

Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD

Terminated·Lundbeck·Phase 1·NCT03819699·3 enrolled

Fibromyalgia1 trial

A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia

Terminated·Lundbeck·Phase 1·NCT04974359·3 enrolled

Schizoaffective Disorder1 trial

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

Completed·Lundbeck·Phase 1·NCT02901587·119 enrolled

Impairment1 trial

Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects

Completed·Lundbeck·Phase 1·NCT03189615·24 enrolled

Ataxia1 trial

Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia

Completed·Lundbeck·Phase 2·NCT01016366·36 enrolled

Post-Traumatic Stress Disorder, PTSD1 trial

Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)

Completed·Lundbeck·Phase 1·NCT04597450·35 enrolled

Congenital Adrenal Hyperplasia1 trial

A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

Recruiting·Lundbeck·Phase 1/2·NCT05669950·42 enrolled

Multiple Sclerosis1 trial

A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis

Terminated·Lundbeck·Phase 1·NCT04990219·37 enrolled

Parkinson's Disease1 trial

Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

Completed·Lundbeck·Phase 1·NCT03611569·74 enrolled

Single Dose1 trial

Single Dose of Lu AF28996 to Healthy Young Men

Completed·Lundbeck·Phase 1·NCT03565094·39 enrolled

Headache1 trial

A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects

Completed·Lundbeck·Phase 1·NCT04976309·25 enrolled

Single Ascending Dose1 trial

Single Ascending Dose Study of Lu AF76432 in Healthy Young Men

Completed·Lundbeck·Phase 1·NCT03531229·42 enrolled

Generalized Anxiety Disorder1 trial

Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder

Completed·Lundbeck·Phase 3·NCT00788034·459 enrolled

Allergies1 trial

A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen

Completed·Lundbeck·Phase 1·NCT05126316·30 enrolled

Epilepsy1 trial

A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy

Terminated·Lundbeck·Phase 1·NCT05081518·1 enrolled

Multiple System Atrophy1 trial

A Study of Lu AF82422 in Participants With Multiple System Atrophy

Active, not recruiting·Lundbeck·Phase 2·NCT05104476·64 enrolled

Hepatic Impairment1 trial

Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects

Completed·Lundbeck·Phase 1·NCT02231450·24 enrolled

Tics1 trial

Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects

Completed·Lundbeck·Phase 1·NCT02122692·20 enrolled

Renal Impairment1 trial

Pharmacokinetics of Lu AF35700 in Subjects With Renal Impairment

Terminated·Lundbeck·Phase 1·NCT03241147·23 enrolled

Oral1 trial

Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700

Completed·Lundbeck·Phase 1·NCT02333487·22 enrolled

Alzheimer's Disease (AD)1 trial

A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

Terminated·Lundbeck·Phase 1·NCT03668405·18 enrolled

Drug1 trial

Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes

Completed·Lundbeck·Phase 1·NCT03195946·24 enrolled

Cushing's Disease1 trial

A Phase II, Multi-site, Open-label, Dose-titration Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AG13909 in Adults With Cushing's Disease

Active, not recruiting·Lundbeck·Phase 2·NCT06471829·16 enrolled

Thyroid Eye Disease1 trial

Interventional, Open-label, Single-group, Long-term Follow-up Trial of Lu AG22515 in Patients With Moderate-to-severe Thyroid Eye Disease

Active, not recruiting·Lundbeck·Phase 1·NCT06557850·20 enrolled

Unspecified11 trials

Safety and Tolerability of Lu AF95245 in Healthy Young Men

Terminated·Lundbeck·Phase 1·NCT04199585·18 enrolled

A Study to Evaluate Lu AF90103 in Healthy Men

Terminated·Lundbeck·Phase 1·NCT04940949·15 enrolled

Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men

Completed·Lundbeck·Phase 1·NCT04082325·68 enrolled

Show 8 more trials

Safety and Tolerability of Lu AG06479 in Healthy Young Men

Terminated·Lundbeck·Phase 1·NCT04473651·46 enrolled

Safety and Tolerability of Lu AG06474 in Healthy Young Men

Completed·Lundbeck·Phase 1·NCT05003687·79 enrolled

A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men

Completed·Lundbeck·Phase 1·NCT06337110·8 enrolled

Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects

Completed·Lundbeck·Phase 1·NCT01975779·42 enrolled

Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167

Completed·Lundbeck·Phase 1·NCT02260830·28 enrolled

Absolute Bioavailability of Lu AE58054 in Healthy Subjects

Completed·Lundbeck·Phase 1·NCT02019394·10 enrolled

A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

Completed·Lundbeck·Phase 1·NCT04104503·33 enrolled

Bioequivalence Study of Lu AF35700

Completed·Lundbeck·Phase 1·NCT03394482·87 enrolled

Details

Drug Info

Related News